NEW YORK, Sept. 13 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that Chief Executive Officer, Robin Smith, M.D., MBA, will present on the Company's latest strategic developments at Rodman & Renshaw's 12th Annual Healthcare Conference at the New York Palace Hotel in New York City on September 13-15, 2010.
Dr. Smith is scheduled to present on Monday, September 13th, from 10:25am to 10:45am in the Garrison Salon on the 5th Floor.
Leading emerging growth biotechnology companies will present at the conference, which will unite companies with institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities.
"I am always excited to present at this annual conference, as it is an opportunity to reach hundreds of the industry's most influential professionals as well as sophisticated investors looking to capitalize on next generation healthcare companies. It is an opportunity to share our progress over the past year as well as our pathway for future outlining milestones to track our expansion progress," said Dr. Robin Smith, CEO and Chairman of the Board of NeoStem.
About NeoStem, Inc.NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include the future of VSEL™ Technology as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic and other filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.NeoStem, Inc.Robin Smith, CEO Phone: +1 (212) 584-4174 E-mail: firstname.lastname@example.org://www.neostem.com
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved